envofolimab + BD0801 + docetaxel

This drug is a combination regimen consisting of **envafolimab** (KN035), **BD0801** (also known as suvemcitug), and **docetaxel**. - **Envafolimab** is a subcutaneously administered, humanized single-domain monoclonal antibody targeting PD-L1, acting as an immune checkpoint inhibitor, designed to restore antitumor immune responses by blocking the interaction between PD-L1 and PD-1. - **BD0801** (suvemcitug) is a humanized rabbit monoclonal IgG1 antibody that targets and neutralizes vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and tumor growth. - **Docetaxel** is a standard chemotherapeutic agent, a small molecule that stabilizes microtubules, leading to disruption of cell division and induction of apoptosis in cancer cells. This combination is under investigation in phase II clinical trials for solid tumors, including hepatocellular carcinoma, by leveraging dual immunotherapy and anti-angiogenic effects along with cytotoxic chemotherapy[2][4][5][6]. All three agents are developed and/or manufactured by companies based in China, notably Simcere Pharmaceutical Group, Alphamab Oncology, and 3D Medicines, with Simcere being implicated in both development and manufacturing roles for these drugs.

Brand names

ENWEIDA

Other names

envafolimabKN035KN-035KN 035suvemcitug